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Sudden cardiac death (SCD) is an unexpected sudden death due to
a heart condition, that occurs within one hour of symptoms onset.
SCD is a leading cause of death in western countries, and is respon-
sible for the majority of deaths from cardiovascular disease. More-
over, SCDaccounts formortality in approximately half of all coronary
heartdiseasepatients. Nevertheless, the recentadvancementsmade
in screening, prevention, treatment, andmanagement of the under-
lying causes has decreased this number. In this article, we sought
to review established and new modes of screening patients at risk
for SCD, treatment and prevention of SCD, and the role of new tech-
nologies in thefield. Further, wedelineate the current epidemiologic
trendsandpathogenesis. Inparticular,wedescribe theadvancement
inmolecular autopsy and genetic testing, the role of target tempera-
ture management, extracorporeal membrane oxygenation (ECMO),
cardiopulmonary resuscitation (CPR), and transvenous and subcuta-
neous implantable cardioverter devices (ICDs).
Keywords
Sudden cardiac death; Sudden cardiac arrest; Cardiopulmonary resuscitation;
Transvenous and subcutaneous implantable cardioverter devices; Extracorpo-
realmembrane oxygenation
1. Introduction
Sudden cardiac death (SCD) is an unexpected sudden
death due to a heart condition, which is almost always con-
firmed upon post-mortem examination. The unexpected
death occurs within one hour of symptom onset and is at-
tributed to a cardiac cause [1, 2]. SCD weighs heavily on
the health care system and the lives of many families. It is
a leading cause of death in western countries (15-20%) and
is responsible for the majority of deaths from cardiovascular
disease [3]. However, its incidence is decreasing due to the
continued advancement in prevention, treatment, and man-
agement. The ever growing use of implantable cardioverter
devices (ICDs) has been a major factor in seeing these num-
bers decline recently [4]. Coronary artery disease (CAD) con-
tinues to be the main pathology associated with SCD, how-
ever deaths from CAD have notably declined over the past
decades. Advances in acute treatment strategies and preven-
tion have driven this decline. Consequently, the incidence
of SCD and CAD have been declining in parallel. Increasing
knowledge and research is improving our understanding of
the mechanisms around the disease (Fig. 1) [5].
2. Epidemiology
Each year, approximately 0.1% of the population (in
United States and Europe) experience a medical services-
assessed, out-of-hospital cardiac arrest [1, 6]. Sudden cardiac
arrest (SCA) is more likely to occur in males and between the
ages of 66 and 68 [7]. SCD in young athletes is rare but is still
a notable cause of death. Early morning and late afternoon
show circadian peaks for deaths andMonday is the day of the
week with the most deaths [8].
Data from other parts of the worlds is limited, however,
it may be fair to predict that the proportion of CAD-related
SCD parallels the incidence of CAD mortality as it has been
shown in western countries (Fig. 2). This is evidenced in
Japan, known for having low incidence and deaths fromCAD
and hence low SCD rates. Additionally, there is a lot of geo-
graphical variation in CAD-related SCD, with possibly high
rates in Central Asia, Oceania and Eastern Europe [3].
Different studies have demonstrated that maximal oxy-
gen uptake (VO2 max), an indicator of cardiorespiratory fit-
ness, is an independent predictor of the risk of SCD [9, 10].
Similarly, exercise-induced ST-segment depression and pro-
Fig. 1. Incidence, Etiology (coronary artery disease, cardiomyopathy, channelopathies, etc.). Prevention (beta-blockers, amiodarone, implantable
cardioverter-defibrillator, coronary revascularization) and future directions of treatment for Sudden Cardiac Death.
longed QRS duration in resting individuals are predictors
of SCD [9, 11]. Other classic independent factors associ-
ated with SCD are: smoking, previous myocardial infarction
(MI), type 2 diabetesmellitus, bodymass index, systolic blood
pressure, and C-reactive protein [11]. Interestingly, frequent
sauna bathing is associated with a reduced risk of SCD, CVD,
and all-cause mortality [10].
3. Etiology
Undetected cardiovascular diseases account for themajor-
ity of SCD cases [12, 13]. Congenital heart defects causing
SCD ismore prevalent in younger people [14]whereas, coro-
nary artery disease is the major contributor to SCD cases in
individuals over 35 years of age [5]. CAD is involved in 80%
cases, making it the most common cause of SCD, while car-
diomyopathies and genetic channelopathies are prominent
remaining causes [15]. The predominant mechanism of SCD
is a form of ventricular arrhythmia (VA). Ventricular ar-
rhythmias are responsible for 84% of SCD. The most com-
mon type of ventricular arrhythmias that lead to SCD are VT
and VF [16]. Nevertheless, pulseless electrical activity (PEA)
and bradyarrhythmia could as well lead to SCD and SCA [17].
At autopsy, coronary artery disease (CAD), hypertrophic
cardiomyopathy (HCM) with or without obstruction, and
valvular aortic stenosis are the most common causes of SCD.
A small percentage of cases, however, show no structural
changes (Table 1) [5].
3.1 Structural etiology
SCD accounts for approximately half of all CAD-related
deaths, and CAD is thought to be the structural cause of ap-
proximately 80% of all SCD. This of course varies for age,
gender, race, and ethnicity. In the Oregon SCD Study, CAD
was the second most common condition (22%) underlying
SCD among subjects aged 5 to 34 years. The spectrum of
substrates underlying CAD-related SCD include transient is-
chaemia, acute coronary syndromes, scar-related pathophys-
iology, and ischaemic cardiomyopathies [19].
The risk of SCD is greatest in the first month following
a myocardial infarction and decreases over time, although
those who develop ventricular remodelling and heart failure
(HF) have a subsequent increase in risk. However, two-thirds
of CAD-related SCD occurs as the first clinical manifestation
in supposedly low-risk individuals based on current risk pre-
diction methods, thwarting efforts to reduce the burden of
CAD-related SCD [20].
Ischaemic heart disease (IHD) is most commonly due
to atherosclerotic CAD. Anomalous coronary arteries with
variations in origin or course, are uncommon but are partic-
ularly seen in SCDs among athletes. Anomalies with obligate
ischaemia (e.g. left main coronary artery arising from pul-
monary artery) are rare beyond infancy while those variants
without obligate ischaemia but with malignant courses (e.g.
between aorta and pulmonary artery) may present in older
cohorts [5].
Non-ischaemic cardiomyopathies implicated in SCD in-
clude HCM, dilated cardiomyopathy, restrictive cardiomy-
opathy, arrhythmogenic right ventricular cardiomyopathy
(ARVC) and left ventricular non-compaction, a rare car-
diomyopathy due to abnormal myocardial formation during
early embryogenesis [21, 22]. Approximately 15% of over-
all SCD occurs in patients with other non-ischaemic struc-
tural heart disease in western society. These include dilated
cardiomyopathies, HCM, ARVC, infiltrative diseases (sar-
coidosis, amyloidosis), myocarditis, and congenital abnor-
malities. It is clear that SCD caused by non-ischaemic car-
diomyopathies is higher in younger populations (15-30% of
SCD in under 35’s) [22–24].
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Valvular heart disease causes SCD in two ways; mechani-
cal and arrhythmogenic. New data suggests that severe aor-
tic stenosis poses a risk of 5-7% for SCD. Mitral valve pro-
lapse has long been associated with SCD due to ventricular
arrhythmias with an estimated risk of 0.2-1.9% but the inci-
dence is poorly defined [25].
Fig. 2. Global incidence of SCD. Incidence demonstrated is from selected
studies reporting SCD in all age groups, with the exception of India (Srivatsa
2016; 35 years old) and Cameroon (Bonny 2017; 18 years old). Abbreviation:
SCD, sudden cardiac death [3].
3.2 Non-structural (arrhythmic) causes of SCD
SCD can occur with a structurally normal heart and in
these cases, the inherited arrhythmia syndromes are the usual
culprits. Genetic mutations in the ion channels of the my-
ocardial cell membrane predispose to malignant arrhyth-
mias and sudden death. The most common cardiac chan-
nelopathies are congenitallike long QT syndrome (LQTS),
Brugada syndrome, catecholaminergic polymorphic ventric-
ular tachycardia (CPVT), and short QT syndrome (SQTS)
[26]. In these cases, the heart is structurally normal, and the
pathology is molecular. There are mutations in genes en-
coding cardiac ion channel proteins. These ion channel dis-
eases increase risk of ventricular fibrillation due to the unsta-
ble electrical cardiac activity. In non-structural SCD, clinical
screening and genetic testing of family members are impor-
tant [27].
A detailed post-mortem examination, with molecular bi-
ology techniques is essential as the only opportunity for a cor-
rect diagnosis according to the guidelines for autopsy inves-
tigation of SCD proposed by the Association for European
Cardiovascular Pathology [28].
4. Pathology
Ventricular fibrillation (VF) is the underlying mechanism
in most SCD. The most common cause of VF is acute coro-
nary ischemia whereas increased risk of ventricular tachycar-
dia (VT) commonly occurs in patients with structural heart
disease as well as channelopathies [29]. A myocardial scar
from a previous infarct is the number one cause of sustained
monomorphic VT in patients with structural heart disease.
Sudden death in these patients frequently results from VT
which eventually leads to VF [29].
Metabolic derangement and oxidative stress particularly
during myocardial ischemia may lead to SCD. Impaired my-
ocyte metabolism and increases in reactive oxygen species,
lead to malfunction of ionic homeostasis in cardiac myocytes,
that in turn cause ventricular tachyarrhythmias and subse-
quently SCD [30]. Following MI, the major causes of SCD
are tachyarrhythmias, re-infarction, and myocardial rupture.
Nonetheless, the risk for SCD declines as time passes [31].
Another potential unifying mechanism for SCD is a
marked release of catecholamines during the stress response.
Massive activation of the sympathetic nervous system leads to
alteration in myocyte intracellular calcium handling, which
in turn leads to ventricular arrhythmias and subsequent SCD
[32]. It has been hypothesized that autonomic nervous sys-
tem activation during sleep triggers arrhythmias that lead to
SCD [18]. In patients with heart failure (HF), in addition
to neurohumoral signaling alterations, there is abnormal ex-
pression of ion channels, which predisposes patients to ven-
tricular arrhythmias, and consequently to SCD [33]. Animal
models have shown downregulation of potassium channels
and abnormal regulation of calcium channel in myocytes of
a failing heart [34, 35]. It appears that increased sympathetic
innervation in failing heart also predisposes patients to ar-
rhythmias [36].
SCD is triggered by a loss of function of one or more of
the four vital systems: heart, brain, lungs, and vasculature
system. Failure of one of the four causes the cessation in
function of the others. For example, in ventricular fibrilla-
tion (VF), failure of the heart to circulate blood causes the
brain, lungs, and vasculature to fail. In contrast, the collapse
of the vascular system may lead to failure of the lungs and
brain, as well as to PEA. Similarly, excess anesthesia leading
to central nervous system arrest, leads to a pulmonary arrest,
followed by vascular and cardiac arrest [37].
5. Clinical features
SCA often occurs without any warning. SCA and SCD
signs and symptoms are immediate and drastic and include
loss of consciousness, sudden collapse, pulsesness, and lack
of breathing [38]. Reduced cerebral blood flow during SCA
causes unconsciousness within seconds. Other symptoms, if
present, are nonspecific and include palpitations, chest pains,
shortness of breath, and weakness.
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Table 1. Primary pathologies related to SCD according to patient age [18]
Age Primary pathology
From birth to 13 years A congenital abnormality such as Tetraology of Fallot.
14 to 34 years Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, congenital coronary anomalies, genetic
channelopathies, myocarditis, Wolff-Parkinson-White syndrome, and Marfan syndrome.
Over 35 years Coronary heart disease.
Table 2. Tests that should be done following SCA [39]
Examination Purpose
Electrocardiogram Diagnosis of ischemic heart disease, Myocardial infarction and inherited channelopathies.
Echocardiogram Can show signs of heart failure, cardiomyopathy, Valvular heart disease and congenital heart disease.
Coronary angiography Evidence of coronary artery disease, congenital abnormalities, and coronary spasms.
Exercise test Can illustrate ischemic heart disease, LQTS and CPVT.
Electrophysiology Detect suspected arrhythmia. Procainamide can provoke Brugada syndrome regardless of the findings on the initial
electrocardiogram.
Cardiac CMR To show ARVC, sarcoidosis (fibrotic cardiomyopathy), myocarditis, and myocardial injury from coronary spasms.
Genetic testing If cardiomyopathy, Brugada syndrome, CPVT, or LQTS are found.
Cardiac biopsy Can be considered.
ARVC, arrhythmogenic right ventricular cardiomyopathy; CMR, Cardiac magnetic resonance; CPVT, catecholaminergic polymorphic ven-
tricular tachycardia; LQTS, long QT syndrome.
6. Clinical assessment of a patient with SCA
6.1 Evaluation of a patient with SCA
Before transportation to a hospital, whenever possible, an
automated external defibrillator (AED) should be attached to
the patient. Cardiac monitoring using an electrocardiogram
(ECG) should begin on arrival of Emergency Medical Ser-
vices. Once the patient is admitted to hospital, full cardiac
assessment should be carried out. A cause should be estab-
lished while the patient should be further stabilised. Table 2
describe the tests that should be done in survivors of SCA
[39].
6.2 Premorbid history
Up to half of SCA patients report no symptoms prior to
collapse. Some patients report palpitations, dizziness, or near
syncope before SCD. Moreover, heart murmurs, heart rate
or blood pressure irregularities, or physical stigmata of Mar-
fan syndrome, might be evident [2, 40]. Table 3 summarizes,
ceratin findings thatmight be evident in patients’ medical and
family history [2, 40].
6.3 Autopsy and postmortem genetic testing
Autopsy in cases of sudden death is essential to determine
whether death is caused by cardiac disease or non-cardiac dis-
eases, such as intracranial hemorrhage and pulmonary em-
bolism. Furthermore, an autopsy can determine the mecha-
nism of the SCD: arrhythmic (mostly ventricular fibrillation),
or mechanical (i.e. cardiac tamponade, pulmonary throm-
boembolism, etc.). Therefore, an autopsy is recommended to
all cases where SCD is suspected or established [6]. Nonethe-
less, clinical information, such as gender, age, circumstances
of death, past medical history, serum enzymes, and ECG trac-
ing during resuscitation, can also facilitate to determine the
cause of death [41].
Standard gross examination of the heart including coro-
nary artery patency assessment andmultiple histological sam-
plings are routinely performed. In cases of clinical history or
ECG tracing suggestive of an unusual conduction abnormal-
ity, it is advised to refer the heart to a specialist center for
histological assessment of the conduction system [41].
Toxicology screen, chemistry, and microbiology workup
are required to establish a definitive diagnosis, whereas il-
licit or prescription drug overdose, anaphylaxis, diabetic ke-
toacidosis, andmyocarditis should be excluded as the cause of
death (Fig. 3). Genetic testing has an emerging role, particu-
larly in cases of sudden death in children and young adults.
Certain genetic diseases causing SCD are associated with
structural heart abnormalities, while others could be harder
to detect. Many of these genetic conditions are inherited in
an autosomal dominant fashion rendering genetic testing an
important role in family member risk and screening [18, 41].
Other, non-cardiac causes of death leading to a sudden death
include stroke and aortic syndromes - all of which must be
considered and ruled out during the post-mortem examina-
tion.
7. SCD risk stratification and genetics
The risk of SCD depends on multiple factors and may
changemarkedly over time. Hence, patients have to bemoni-
tored continuouslywithmore than one assessment tool. Cur-
rent guidelines recommend clinical history and physical exam
in combination with invasive and non-invasive diagnostic
exams to evaluate patients’ risk for SCD. Important factors
that should be considered in assessing patients’ clinical history
are age, previous documented or symptoms of an adverse car-
diac event such as HF, CAD, and sustained or non-sustained
ventricular tachycardia. In particular, syncope is an impor-
tant indicator for further evaluation andmanagement [2, 43].
Risk factors for heart disease, as well as antiarrhythmic medi-
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Table 3. Common evidence suggestive of sudden cardiac death, in patients’ medical history and patients’ family medical
history [2, 40]
Signs and symptoms in medical history Common findings in family medical history
Exertional symptoms such as dyspnea/fatigue or palpitations. Premature death or disability before age 50 attributed to heart disease in a
relative.
Syncope or seizures Cardiac diseases, such as hypertrophic or dilated cardiomyopathy, chan-
nelopathies, Marfan syndrome, or clinically significant arrhythmia.
Chest pain/discomfort/tightness/pressure related to exertion related or
not related to exertion
Epilepsy or syncope.
Intercurrent illnesses and any known cardiac investigations, such as elec-
trocardiogram or cardiac imaging, which must be reviewed where avail-
able.
Elevated blood pressure
History of drug use (prescribed or illicit)
Table 4. Electrocardiogrammarkers for sudden cardiac death risk stratification
Definition References
Microvolt T-wave alternans (MTWA) T-wave duration difference between alternate beats at the microvolt level [21, 46]
T-peak–T-end interval The interval from the peak to the end of the T-wave [21, 47]
QRS fragmentation Presence of an R’ wave or spikes in the QRS complex. [21, 47]
QRS duration Duration of the QRS complex [21, 47]
cations, medications with potential for QT prolongation, and
substance abuse such as cocaine and anabolic steroids should
be evaluated. On physical examination, attention should be
devoted to heart rate and blood pressure, murmurs, and jugu-
lar venous pressure [2, 43].
SCD risk stratification exam can be subdivided into in-
vasive; which mostly consists of electrophysiology (EPS),
and noninvasive; 12-leads ECG, image techniques, Holter
ECG, high-resolution ECG, and stress test. The EPS utilizes
catheters to record the internal cardiac electric activity dur-
ing induced ventricular arrhythmias. It is mainly used as part
of catheter ablation, or if SCA cause is unestablished using
other techniques. In the past studies have shown that com-
bining this exam in the screening process might reduce SCD
rate in patients with CAD [44, 45]. Nonetheless, EPS relia-
bility in predicting SCD due to ventricular fibrillation or flut-
ter is questionable. Moreover, its negative predictive value is
dependent on the ventricular stimulation protocol [45]. In
recent guidelines, EPS is not favored over clinical assessment
and non-invasive studies, for the risk stratification of SCD
[2].
ECG, a widely available exam, can be helpful for the di-
agnosis of channelopathies and cardiopathies [2]. More-
over, electrocardiogram markers such as microvolt T-wave
alternans (MTWA), QRS fragmentation, QRS duration, and
signal-averaged ECG, have been demonstrated to correlate
with risk for SC [21, 46, 47]. Table 4 summarize ECG mark-
ers important for SCD risk stratification. ECG also plays a
crucial role in the management of SCA, and MI, hence in the
acute prevention of SCD [2].
Holter or continuous ambulatory electrocardiography are
analyzed to detect ventricular extrasystoles, ventricular pre-
mature beats, atrial fibrillation, ventricular tachycardia (VT),
as well as T wave alternans, heart rate turbulence, or heart
rate variability indices, whose alterations can promote ven-
tricular arrhythmias. Ambulatory electrocardiography is rec-
ommended for 24 hours for symptomatic patients [2].
Echocardiography enables the assessment of cardiac struc-
tures such as cardiac valves, diagnose cardiomyopathies as
well as evaluate left ventricular ejection fraction (LVEF). A
study aimed to evaluate the echocardiography predictor pa-
rameter of SCD found that not only reduced LVEF, but also
mitral annular calcification, mitral E/A > 1.5 or < 0.7, in-
creased left ventricle mass and diameter are associated with
an increased risk of SCD [48]. Hence, echocardigraphy is rec-
ommended for patients with suspected cardiac structural ab-
normality and HF [2]. Cardiac magnetic resonance (CMR)
late gadolinium enhancement (LGE) allows depiction of my-
ocardial fibrosis, a determinant of arrhythmic propensity,
which has been shown to be a stronger prediction factor for
ventricular arrhytmias than LV failure [49].
Genetic testing have also found their way into the screen-
ing and risk stratification of SCD. It is recommended for pa-
tients and family members of patients with channelopathies
and cardiomyopathies [2, 6]. The genetic contribution to
SCD susceptibility can be divided into genetic variants that
are associated with known inherited cardiac disorders, and
genetic variants contributing to susceptibility to SCD but are
not associatedwith a known cardiac disorder or ECGpattern.
Nonetheless, genetic testing can confirm the diagnosis of the
inherited arrhythmic syndrome, which are usually diagnosed
with clinical and familiar history.
KCNQ1 and KNCH2 genes encode for the slowly activat-
ing delayed rectifier current (IKs) and for rapidly activating
delayed rectifier current (IKr), respectively. SCN5A encodes
a subunit of the voltage-gated sodium channel Nav 1.5. Mu-
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Table 5. ICD indication according to AHA/ACC/HRS guidelines [2]
ICD indication according to LVEF and HF symptoms [2]
LVEF NYHA classification
< 35% NYHA class II or III symptoms
< 30% NYHA class I
Patients with LVEF< 40% and inducible sustained VT or VF on EPS
Patients with IHD, unexplained syncope and inducible sustained VT on EPS
EPS, electrophysiological study; HYHA, New York Heart Association classifi-
cation; LVEF, left ventricle ejaculation fraction; VF, ventricle fibrillation; VT,
ventricle tachycardia.
tations in these genes may lead to LQTS and were associated
with SCD [50]. Furthermore, different KCNQ1 and KNCH2
may lead to short-QT Syndrome and increased risk for SCD
[51]. SCN5A, CACNA1C, and CACNB2B (genes encoding
the CaV1.2 L-type calcium channel subunits) mutation are
associated also with Brugada syndrome [52].
CPVT (catecholaminergic polymorphic ventricular tachy-
cardia) is a heritable arrhythmia syndrome, in which patients
often have normal baseline ECG. But during physical activ-
ity or emotional stress, patients might experience, bidirec-
tional or polymorphic VT. Mutation in the ryanodine recep-
tor (RyR2), which is a calcium channel that regulates calcium
ion release from the sarcoplasmic reticulum, is founded in
60% of patients with CPVT [53, 54].
Mutations in MYBPC3 or MYH7, that encode sarcoplas-
mic proteins are one of the genetic causes of the majority of
HCM cases, carries risk for SCD [55].
Genome-wide association studies (GWAS) provided new
biological insight about the genetic association to SCD. In-
stead of a specific mutation, GWAS illuminates a haplotype
association with SCD. A meta-analysis of GWAS data iden-
tified a locus (BAZ2B) that is likely to be involved in gene
regulation correlated to SCD risk [56].
A survey from 2015 aimed to assess how screening and
risk evaluation of patients with risk of SCD was performed
in European centers. This survey indicated that in patients
with CAD and low LVEF the vast majority of centers con-
sidered the ECG and exercise capacity assessment to be fun-
damental for SCD risk stratification. For patients with HCM
or patients with a family history of HCM-related SCD, his-
tory of unexplained syncope or non-sustained VT, low blood
pressure during exercise, and extreme left ventricular hyper-
trophy were the major clinical risk factors [57].
8. Management
Prevention of SCD is the main goal in management, since
the overall survival rate of out of hospital cardiac arrest, and
consequently SCD, is estimated to be 10% [58]. Therefore
targeting individuals at high risk is the main priority as well
as initiating appropriate preventive measures.
8.1 Medications
Except for quinidine, mexiletine, and flecainide for Bru-
gada syndrome, LQTS, and CPVT sodium channel blockers
are not recommended for SCD prevention [59, 60]. CAST
I and CAST II are two clinical trials aimed to examine the
sodium channel blockers’ anti-arrhythmic ability to prevent
SCD. Both studies were prematurely terminated for excess
mortality due to arrhythmias [61, 62]. Similarly, non dihy-
dropyridines calcium channel blockers have no role in SCD
prevention [6]. On the other hand, beta-blockers, and to a
smaller degree amiodarone, are beneficial in the prevention
of SCD. Beta-blockers have shown to reduce the mortality,
not only of patientswithHF andCAD, but also to reduce SCD
and ventricular arrhythmias (VA) incidents [63–65]. More-
over, beta-blockers are also the first-line therapy for previ-
ously mentioned channelopathies (e.g. long e.g. QT syn-
drome) [6]. Intravenous amiodarone is indicated in reduc-
ingVA recurrence during resuscitation and hence preventing
SCD [2]. However, due to its variety of adverse effects and
interactions, it failed to provide strong benefits over a long
period of prescription. Even if it reduced SCD risk and car-
diovascular death, the overall mortality is not reduced [66].
For this reason, periodical monitoring of thyroid, liver, and
lung function are recommended when prescribed for longer
periods [2]. Sotalol, which offers beta-blocking activity with
amiodarone-like action, has a pro-arrhythmic effect which
prevents it from being used in patients’ post-MI or with HF
[6, 67]. Hence, its role in the prevention of SCD and SCA is
limited.
A combination of antiarrhythmic drugs is recommended
in specific cases when other modalities, such as catheter abla-
tion or ICD, have failed [6]. For example, in patients with
drug-refractory VT, Ranolazine has been combined with
other anti-arrhythmics such as amiodarone or sotalol, with
encouraging results [68]. A more frequent approach is pre-
scribing beta-blockers, or less frequently sotalol, to the pa-
tient with an ICD to meliorate their control [6, 69].
Another aspect in the prevention of SCD is the treat-
ment of underlying cardiac disease and comorbidities. For
instance, in a patient with HF it is important to reduce my-
ocardial oxygen consumption and sympathetic tone to reduce
the risk for SCDs. Therefore, beta-blockers, angiotensin-
converting enzyme inhibitors or angiotensin-receptor block-
ers, mineralocorticoid-receptor antagonists, and angiotensin
receptor-neprilysin inhibitors are recommended for SCD
prevention [70, 71]. Similarly, myocardial infarction patients
should receive optimal medication as well (including beta-
blockers, dual antiplatelet therapy, and statins) for reducing
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Fig. 3. Algorithm for Assessment of SCD [42] includes appropriate Premorbid history of decedent, Autopsy with histological and toxological
assessment, molecular and genetic analysis of first-degree relatives as well as identification of structural causes (if any).
SCD risk [6]. Furthermore, addressing electrolytes distur-
bance, especially potassium andmagnesium, in patients post-
MI and with HF reduces SCD risk [6, 72].
8.2 ICD
ICDs continuouslymonitor heart activity and are effective
in terminating life-threatening VA. To this date, the main-
stay of SCD prevention is ICD. Indication for ICD can be
grouped as primary prevention and secondary prevention.
Primary SCD prevention, targets patients with no clinical
history of ventricular arrhythmias, but are at high risk for
SCD. While secondary prevention targets patients who sur-
vived SCA. Both groups of patients are evaluated with the
tools discussed before, to determine the need for an ICD. A
five year followup comparing ICD in patients with primary
and secondary indications demonstrated comparable mortal-
ity in both groups. Nevertheless, it appears that patients with
secondary indications had more incidents of VA that were
terminated by ICD [73].
While in most cases ICD is recommended for secondary
prevention, primary prevention indications are more com-
plicated. Nevertheless, patients of both groups require more
than 1 year of life expectancy and non-reversible VA etiol-
ogy (such as electrolytes abnormality) to be eligible for ICD
[2, 6, 57]. For instance, ICD is recommended only after 40
days post-MI or at least 90 days post revascularization, based
upon the belief that left ventricular function can improve fol-
lowing these events, and consequently SCD risk will decrease
[74]. In addition, ICD indications are based on LVEF and HF
symptoms as classified in NYHA classification (Table 5) [2].
Transvenous ICD (T-ICD) is most widely used, and it is
beneficial for patients with a life expectancy of more than
1 year, related complications are inappropriate shock and
device-related infections [75]. Subcutaneous ICD (S-ICD)
is an alternative for T-ICD. It should be considered in pa-
tients unfitted to T-ICD, due to inability to access the vas-
cular system when pacing therapy for bradycardia support,
cardiac resynchronization, or when anti-tachycardia pacing
is not needed [54, 76]. Another alternative is an external
ICD (a wearable pads and electrodes). This devices efficiency
hasn’t been validated yet, hence it is recommended only as a
temporary solution, bridging for cardiac transplant or T-ICD
implantation [6].
However, two clinical studies might change the percep-
tion that S-ICD is only indicated for the patients who are
found to be unfitted for T-ICD. The PRAETORIAN trial that
enrolled 876 patientswho randomly received either an S-ICD
or T-ICD, and were followed up for about 4 years, and UN-
TOUCHED trial a prospective non-randomized study that
followed 1116 patient who received S-ICD, for 18 months.
The PRAETORIAN study found that S-ICD was equivalent
to the T-ICD with respect to device-related complications
and inappropriate shocks rates. Furthermore, the rates of
SCDwere equal in both S-ICD and T-ICD groups. Similarly,
the UNTOUCHED study demonstrated high S-ICD efficacy
and safety [77, 78].
8.3 Catheter ablation
While ICD can terminate VA, it cannot prevent VA from
reoccurring like catheter ablation can accomplish. Catheter
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ablation is particularly valuable for patients with scar tissue
related to VF or VT [79]. In patients with no structural heart
abnormalities, VT ismost commonlymonomorphic and typ-
ically originate from one focal point, commonly at the ven-
triclar (right or left) outflow tract. On the other hand, in pa-
tients with structural heart disease, VT is more commonly
due to scar tissue reentry mechanism, and on ECG their VT
is also monomorphic (Polymorphic VT is more likely due to
acute MI or channelopathies). The procedure is more effec-
tive in patients without structural heart abnormalities than
patients with structural heart abnormalities. However, 22%
of patients without structural heart abnormality and 15% of
the patients with structural heart abnormality will require re-
peated ablation [80]. Common procedural complications are
correlated to access sites, such as groin hematoma and pseu-
doaneuysm [80].
8.4 Acute management of ventricular arrythmias and prevention
of SCD
When dealing with acute cardiac arrest, time is key. Sur-
vival decreases from 25% after 4-5minutes to 0% after 10min
[81]. According to the American Heart Associaiton, in pa-
tientswith ventricular arrhythmiaswith hemodynamic insta-
bility, defibrillation should be performed as quickly as possi-
ble, while cardiopulmonary resuscitation (CPR) is used until
a perfusing rhythm is restored [2]. In out-of-hospital car-
diac arrest, CPR should be performed immediately until the
defibrillator is available, unlike in-hospital cases in which de-
fibrillation should occur first [6]. If the patient remains ar-
rhythmic after 3 shocks, amiodarone should be administered
[2]. On the other hand, an ECG should be obtained for sta-
ble patients, as well as perfusion, and respirations should be
assessed [2, 6]. Post-resuscitation care includes, vital-organ
support, targeted temperature management and exploring
underlying cause.
8.5 Revascularization
According to the American Heart Association guidelines,
patients with sustained VA and survivors of SCA should be
evaluated for ischemic heart disease, and should be revascu-
larized as appropriate [2]. It appears that although revascu-
larization improves survival, there is no difference between
coronary artery bypass graft or percutaneous coronary in-
tervention (PCI) in the prevention of SCD [82, 83]. More-
over, it appears that survival and neurological outcomes are
better for patients who underwent coronary angiogram in
the first 24 hours after regaining spontaneous circulation
(ROSC) [84].
However, the Coronary Angiography after Cardiac Arrest
Trial (COACT), a randomized clinical trial that included 552
patients, showed there was no significant difference in clin-
ical outcomes at 1 year between patients in the immediate
angiography group compared with patients whose angiogra-
phy was delayed until after neurologic recovery. Survival at
1 year was 61.4% in the immediate group versus 64.0% in the
delayed group [85].
8.6 Targeted temperature management
Targeted temperature management (TTM), also known
as induced hypothermia, is shown to be beneficial for im-
proving outcomes in patients post-resuscitation. It can be
delivered by several methods: surface cooling ranges from
ice packs and cooling pads to air mattresses, while inter-
nal cooling includes specialized endovascular heat-exchange
catheters and intravenous fluids [86]. A large randomized
controlled trial from 2013 aimed at determining the most
beneficial temperature demonstrated no difference in out-
comes when using 33 ◦C versus 36 ◦C target temperature
[87]. Moreover, a randomized control study from 2019,
demonstrated that TTM is not only beneficial after shockable
cardiac arrest (VT/VF), as had been previously postulated,
but also for non-shockable cardiac arrest (asystole/pulseless
electrical activity [88]. Regarding the duration of TTM, it
has been demonstrated to have similar outcomes for 24 and
48 hours [89].
8.7 Combined targeted temperature management and coronary
angiography
Asmentioned previously, coronary angiography is part of
the post-cardiac arrest evaluation. A recent retrospective co-
hort study fromTaiwan demonstrated increased survival and
neurological outcome in patients who underwent coronary
angiography in the first 24 hours, as well as TTM [84].
8.8 Prognosticating factors after sudden cardiac arrest
For survivors of SCA, factors associated with poor neu-
rological outcomes for out-of hospital cardiac arrrest include
advanced age, unwitnessed arrest, no bystander CPR, time
to achievement of ROSC > 30 min, arterial pH < 7.2, non
shockable rhythm, serum lactate levels > 7 mmol/L, ESRD
(end stage renal disease), and high cardiac arrest hospital
prognosis (CHAP) score [90].
8.9 Sudden Cardiac Death in young atheletes
Hypertrophic cardiomyopathy (HCM) is the most com-
mon cardiac abnormality implicated in SCD in young athletes
< 35 years old in the United States followed by congenital
anomalies of the coronary artery and arrhythmogenic right
ventricular cardiomyopathy. Soccer has been unfortunately
plagued in recent years by deaths at the professional level dur-
ing internationally televised games. Hence, athletic pre par-
ticipation screening has been made essential for minimizing
the risk for sudden cardiac death (SCD) in them. The car-
diovascular screening for HCM includes personal and family
history, physical examination, a 12-lead resting ECG, as well
as an exercise ECG and an echocardiogram [91].
9. Future directions
As mentioned previously, once a patient is experiencing
SCA, CPR should be done to prevent SCD.Nonetheless, CPR
efficiency decreases with time, and after 20 minutes of CPR
the survival probability decrease by ten times [92]. There-
fore, new methods are being explored to improve this aspect
in patient care.
154 Volume 22, Number 1, 2021
9.1 Mechanical chest compressions (MCC)
As discussed previously, chest compressions as part of
CPR are essential in the management of cardiac arrest. Nev-
ertheless, the quality of manual chest compression during
CPR may be impaired by CPR provider fatigue and by am-
bulance movement [93, 94]. To overcome these issues, de-
vices that provide mechanical chest compressions (MCC)
have been recently introduced. These devices can be sub-
divided into three categories: point compression, load dis-
tribution compression, and full chest compression. Recent
meta-analyses found no advantage of these devices overman-
ual CPR compression, in the reduction of SCD rate, as well
as long term mortality and complication of SCA [95, 96].
LUCAS (Lund University Cardiopulmonary Assist) device is
commonly used device for this purpose.
9.2 ECMO and eCPR
In the survival of chain for out-of-hospital cardiac arrest,
the goal of CPR is to establish ROSC so as to provide end-
organ perfusion and prevent secondary brain damage. Re-
cently, insertion of venoarterial extracorporeal membrane
oxygenation (VA-ECMO) during CPR to rapidly provide cir-
culatory support termed extracorporeal cardiopulmonary re-
suscitation (eCPR) has been tried especially in younger pa-
tients who do not achieve ROSC after 10-15minutes of CPR.
It is a very resource-sensitive strategy, performed only by
few experienced centers and cannot be applied to all SCA
patients. Napp et al. [97] analyzed 40 patients with refrac-
tory OHCA and potentially favorable circumstances who un-
derwent eCPR. Overall 30-day survival was 12.5%, with 3 of
5 survivors having a favourable neurological outcome. No
patient selected for eCPR met all pre-defined criteria. Im-
portantly, time-to-ECMO most often exceeded 60 minutes
(mean 102 ± 32 min), and lactate was > 15 mmol/L in 30
out of 40 patients. Moreover, 22 out of 40 patients had a non-
shockable rhythm on the first ECG [97].
9.3 PCI during CPR
PCI in patients undergoing CPR after sudden cardiac ar-
rest can be used as a part of the resuscitation effort to address
the underlying cause. CPR can be done manually, with me-
chanical chest compression or utilising ECMO. A retrospec-
tive analysis from 2017, showned thatMCC provides a better
outcome than manual CPR in the catheterization lab [98]. In
another study, ECMO when combined with PCI for patients
in cardiac arrest was associatedwith favorable outcomes [99].
Hence, new approaches suggest incorporation of mechanical
chest compression, ECMO, TTM, and early reperfusion in
the management of SCA [100, 101].
9.4 Definitive treatment of underlying causes
While definitinve treatment of individual underlying
cause of SCD are beyond the scope of this review, a few
need worth mentioning. Patients with hypertrophied car-
diomyopathy should be treated with septal ablation or alco-
hol injection procedures. Similarly, patients with severe aor-
tic stenosis require relief of outflow tract obstruction with
some form procedure including balloon aortic valvotomy,
transcatheter aortic valve replacement depending upon their
ability to tolerate these procedures. Additonally, survivors
of acute pumonary embolism need definitive treatment us-
ing procedure like transcatheter guided thrombolysis (EKOS)
or pulmonary thromboendarterectomy utilizing cardiopul-
monary bypass support [102].
10. Conclusions
SCD remains a prominent cause of death. Both congeni-
tal heart disease and heart failure appear to be the important
causes, hence, treatment of these underline conditions and
optimizing the cardiac function is essential in the prevention
of SCD. Genetic testing and MRI are promising modalities
in patients’ screening and risk stratification whereas T-ICDs
are widely used in the prevention of SCD. Strategies such as
targeted temperature management, mechanical chest com-
pressions, eCPR and PCI during CPR, show promise and will
need further validation.
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